Selective activation of PI3Kα/Akt/GSK-3β signalling and cardiac compensatory hypertrophy during recovery from heart failure

European Journal of Heart Failure

Volumn 11, Issue 8, 2009, Pages 739-748

  Braz, Julian C ^a   Gill, Robert M ^a   Corbly, Angela K ^a   Jones, Bonita D ^a   Jin, Najia ^a   Vlahos, Chris J ^a   Wu, Qingyu ^b   Shen, Weiqun ^c  

^a ELI LILLY AND COMPANY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

Cardiac hypertrophy; Cardiac recovery; Heart failure; PI3K ; PI3K

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BETA CATENIN; CELL PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PROTEIN KINASE B; PROTEIN P70S6K; UNCLASSIFIED DRUG; DOBUTAMINE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOG; ENZYME ACTIVATION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART PACING; HEART VENTRICLE CONTRACTION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; LONGITUDINAL STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANALYSIS OF VARIANCE; ANIMAL; HEART LEFT VENTRICLE HYPERTROPHY; HEMODYNAMICS; MALE; PATHOPHYSIOLOGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANALYSIS OF VARIANCE; ANIMALS; DOBUTAMINE; DOGS; GLYCOGEN SYNTHASE KINASE 3; HEART FAILURE; HEMODYNAMICS; HYPERTROPHY, LEFT VENTRICULAR; LONGITUDINAL STUDIES; MALE; MODELS, ANIMAL; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 67749129256     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfp094     Document Type: Article

References (37)

1. Toker A, Cantley LC. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 1997;387:673-676.
2. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296: 1655-1657.
3. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 2004;37:449-471.
4. Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, Lawitts J, Cantley LC, Izumo S. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 2000;19:2537-2548.
5. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Kang PM, Izumo S. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA 2003;100:12355-12360.
6. Luo J, McMullen JR, Sobkiw CL, Zhang L, Dorfman AL, Sherwood MC, Logsdon MN, Horner JW, DePibho RA, Izumo S, Cantley LC. Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol Cell Biol 2005;25:9491-9502.
7. Kaplan ML, Cheslow Y, Vikstrom K, Malhotra A, Geenen DL, Nakouzi A, Leinwand LA, Buttrick PM. Cardiac adaptations to chronic exercise in mice. Am J Physiol 1994;267:H1167-H1173.
8. Konhilas JP, Widegren U, Allen DL, Paul AC, Cleary A, Leinwand LA. Loaded wheel running and muscle adaptation in the mouse. Am J Physiol 2005;289: H455-H465.
9. Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, Sasaki T, Hirsch E, Suzuki A, Shioi T, Irie-Sasaki J, Sah R, Cheng HYM, Rybin VO, Lembo G, Fratta L, Oliveira-dos-Santos AJ, Benovic JL, Kahn CR, Izumo S, Steinberg SF, Wymann MP, Backx PH, Penninger JM. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell2002;110:737-749.
10. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature 2002;415:206-212.
11. Alloatti G, Montrucchio G, Lembo G, Hirsch E. Phosphoinositide 3-kinase gamma: kinase-dependent and -independent activities in cardiovascular function and disease. Biochem Soc Trans 2004;32:383-386.
12. Patrucco E, Notte A, Barberis L, Selvetella G, Maffei A, Brancaccio M, Marengo S, Russo G, Azzolino O, Rybalkin S. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 2004;118:375-387.
13. Nienaber JJ, Tachibana H, Naga Prasad SV, Esposito G, Wu D, Mao L, Rockman HA. Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure. J Clin Invest 2003;112:1067-1079.
14. Tomita M, Spinale FG, Crawford FA, Zile MR. Changes in left ventricular volume, mass, and function during the development and regression of supraventricular tachycardia-induced cardiomyopathy. Disparity between recovery of systolic versus diastolic function. Circulation 1991;83:635- 644.
15. Moe GW, Grima EA, Howard RJ, Seth R, Armstrong PW. Left ventricular remodelling and disparate changes in contractility and relaxation during the development of and recovery from experimental heart failure. Cardiovasc Res 1994;28: 66-71.
16. Shen W, Spindler M, Higgins MA, Jin N, Gill RM, Bloem LJ, Ryan TP, Ingwall JS. The fall in creatine levels and creatine kinase isozyme changes in the failing heart are reversible: complex post-transcriptional regulation of the components of the CK system. J Mol Cell Cardiol 2005;39:537-544.
17. Gill RM, Braz JC, Jin N, Etgen G, Shen W. Enhanced eNOS phosphorylation and cGMP/cGKI signaling contribute to the restoration of endothelial-dependent coronary vascular relaxation in heart failure. Am J Physiol Heart Circ Physiol 2007;292: H2782-H2790.
18. Shen W, Gill RM, Zhang JP, Jones BD, Corbly AK, Steinberg MI. Sodium channel enhancer restores baroreflex sensitivity in conscious dogs with heart failure. Am J Physiol 2005;288:H1508-H1514.
19. Feneley MP, Gaynor JW, Maier GW, Gall SA Jr, Kisslo JA, Rankin JS. In vivo estimation of left ventricular wall volume in volume-overloaded canine hearts. Am J Physiol 1988;255:H1399-H1404.
20. Feldman AM, Weinberg EO, Ray PE, Lorell BH. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ Res 1993;73:184-192.
21. Braz JC, Bueno OF, Liang O, Wilkins BJ, Dai YS, Parsons S, Braunwart J, Glascock BJ, Klevitsky R, Kimball TF, Hewett TE, Molkentin JD. Targeted inhibition of p38 MAPK promates hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J Clin Invest 2003;111:1475-1486.
22. Matsui T, Li L, Wu JC, Cook SA, Nagoshi T, Picard MH, Liao R, Rosenzweig A. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem 2002;277:22896-22901.
23. Condorelli G, Drusco A, Stassi G, Bellacosa A, Roncarati R, Iaccarino G, Russo MA, Gu Y, Dalton N, Chung C, Latronico MV, Napoli C, Sadoshima J, Croce CM, Ross J Jr. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA 2002;99:12333- 12338.
24. Naga Prasad SV, Esposito G, Mao L, Koch WJ, Rockman HA. Gβγ-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. J Biol Chem 2000;275:4693- 4698.
25. Shioi T, McMullen JR, Kang PM, Douglas PS, Obata T, Franke TF, Cantley LC, Izumo S. Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 2002;22:2799-2809.
26. Morisco C, Zebrowski D, Condorelli G, Tsichlis P, Vatner SF, Sadoshima J. The akt-glycogen synthase kinase 3β pathway regulates transcription of atrial natriure-tic factor induced by β-adrenergic receptor stimulation in cardiac myocytes. J Biol Chem 2000;275:14466-14475.
27. Antos CL, McKinsey TA, Frey N, Kutschke W, McAnally J, Shelton JM, Richardson JA, Hill JA, Olson EN. Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 2002;99:907- 912.
28. Dajani R, Fraser E, Roe SM, Young N, Good V, Dale TC, Pearl LH. Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 2001;105:721-732.
29. Haq S, Choukroun G, Lim H, Tymitz KM, del Monte F, Gwathmey J, Grazette L, Michael A, Hajjar R, Force T, Molkentin JD. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 2001;103:670-677.
30. Luckey SW, Mansoori J, Fair K, Antos CL, Olson EN, Leinwand LA. Blocking cardiac growth in hypertrophic cardiomyopathy induces cardiac dysfunction and decreased survival only in males. Am J Physiol Heart Circ Physiol 2007;292: H838-H845.
31. Hirotani S, Zhai P, Tomita H, Galeotti J, Marquez JP, Gao S, Hong C, Yatani A, Avila J, Sadoshima J. Inhibition of glycogen synthase kinase 3b during heart failure is protective. Circ Res 2007;101:1164-1174.
32. Dorn GW II, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005;115:527-537.
33. Fingar DC, Sofie Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 2002;16:1472-1487.
34. Prasad SV, Perrino C, Rockman HA. Role of phosphoinositide 3-kinase in cardiac function and heart failure. Trends Cardiovasc Med 2003;13:206-212.
35. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Dorfman AL, Longnus S, Pende M, Martin KA, Blenis J, Thomas G, Izumo S. Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. Mol Cell Biol 2004;24:6231-6240.
36. Jo SH, Leblais V, Wang PH, Crow MT, Xiao RP. Phosphatidylinositol 3-kinase functionally compartmentalizes the concurrent G(s) signaling during beta2-adrenergic stimulation. Circ Res 2002;91:46-53.
37. Perrino C, Naga Prasad SV, Schroder JN, Hata JA, Milano C, Rockman HA. Restoration of β-adrenergic receptor signaling and contractile function in heart failure by disruption of the βARK1/phosphoinositide 3-kinase complex. Circulation 2005;111:2579-2587.